The II Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19 Joint Guidelines of the Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia and Sociedade Brasileira de Reumatologia Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • OBJECTIVE: To update the recommendations to support decisions regarding the pharmacological treatment of patients hospitalized with COVID-19 in Brazil. METHODS: Experts, including representatives of the Ministry of Health and methodologists, created this guideline. The method used for the rapid development of guidelines was based on the adoption and/or adaptation of existing international guidelines (GRADE ADOLOPMENT) and supported by the e-COVID-19 RecMap platform. The quality of the evidence and the preparation of the recommendations followed the GRADE method. RESULTS: Twenty-one recommendations were generated, including strong recommendations for the use of corticosteroids in patients using supplemental oxygen and conditional recommendations for the use of tocilizumab and baricitinib for patients on supplemental oxygen or on noninvasive ventilation and anticoagulants to prevent thromboembolism. Due to suspension of use authorization, it was not possible to make recommendations regarding the use of casirivimab + imdevimab. Strong recommendations against the use of azithromycin in patients without suspected bacterial infection, hydroxychloroquine, convalescent plasma, colchicine, and lopinavir + ritonavir and conditional recommendations against the use of ivermectin and remdesivir were made. CONCLUSION: New recommendations for the treatment of hospitalized patients with COVID-19 were generated, such as those for tocilizumab and baricitinib. Corticosteroids and prophylaxis for thromboembolism are still recommended, the latter with conditional recommendation. Several drugs were considered ineffective and should not be used to provide the best treatment according to the principles of evidence-based medicine and to promote resource economy.

authors

  • Falavigna, Maicon
  • Araujo, Cintia Laura Pereira de
  • Barbosa, Alexandre Naime
  • Belli, Karlyse Claudino
  • Colpani, Verônica
  • Dal-Pizzol, Felipe
  • Silva, Rosemeri Maurici da
  • Azevedo, Luciano César Pontes de
  • Dias, Maria Beatriz Souza
  • Amaral, José Luiz Gomes do
  • Dorneles, Gilson Pires
  • Ferreira, Juliana Carvalho
  • Freitas, Ana Paula da Rocha
  • Gräf, Débora Dalmas
  • Guimarães, Hélio Penna
  • Lobo, Suzana Margareth Ajeje
  • Machado, Flávia Ribeiro
  • Nunes, Michelle Silva
  • Oliveira, Maura Salaroli de
  • Parahiba, Suena Medeiros
  • Rosa, Regis Goulart
  • Santos, Vania Cristina Canuto
  • Sobreira, Marcone Lima
  • Veiga, Viviane Cordeiro
  • Xavier, Ricardo Machado
  • Zavascki, Alexandre Prehn
  • Stein, Cinara
  • Carvalho, Carlos Roberto Ribeiro de

publication date

  • 2023